POLQ and hematopoietic and lymphoid system neoplasm: To further explore the in vivo antitumor effects of thioparib in blood cancers, we used xenografts of the HR‐proficient MM.1 S cell line, the POLQ mutant MV‐4‐11 cell line, and the BRCA1/2‐deficient JeKo‐1 cell line (Xiao et al, 2008), all of which have different genetic backgrounds and high sensitivity to thioparib.